SECsense Logo

Vistagen Therapeutics 8-K Report: Key Updates for Investors - February 2025

$VTGN
Form 8-K
Filed on: 2025-02-13
Source
Vistagen Therapeutics 8-K Report: Key Updates for Investors - February 2025

Based on the provided section of the financial report, here are the key insights and information extracted:

  1. Company Information:
  • Name: Vistagen Therapeutics, Inc.
  • CIK (Central Index Key): 0001411685
  • SEC File Number: 000-54014
  • EIN (Employer Identification Number): 20-5093315
  • Address: 343 Allerton Ave., South San Francisco, CA 94080
  • Phone Number: 650-577-3600
  • Stock Symbol: VTGN (listed on NASDAQ)
  1. Filing Information:
  • Filing Type: 8-K (Current Report)
  • Filing Date: February 13, 2025
  1. Reporting Period:
  • Period Covered: September 23, 2024
  • Start Date: September 23, 2024
  • End Date: September 23, 2024
  1. Stock Information:
  • Type of Stock: Common Stock
  • Par Value: $0.001 per share
  1. XBRL and Schema Reference:
  • The document is formatted in XBRL (eXtensible Business Reporting Language).
  • Schema Reference: vtgn-20250213.xsd, indicating the structure of the data.

Insights:

  • This filing is an 8-K, typically used to report significant events that shareholders should know about, which could include mergers, acquisitions, or changes in management.
  • The filing date suggests that the company may be disclosing important news shortly after the end of the reporting period, which is indicative of timely communication with investors.
  • The information indicates that Vistagen Therapeutics is a publicly traded company with active operations in the biotechnology sector, given its NASDAQ listing.

This extracted information provides a clear picture of the company’s legal and operational identity, the context of the report, and the financial information relevant to investors and analysts.